How the United States and México regulate stem cell therapy

Comparisons between American and Mexican stem cell regulation usually begin from the wrong premise: that the two countries are running the same kind of system at different levels of strictness. They are not. The two frameworks are organized around different questions, and understanding that difference explains most of what follows.

The United States framework is, at its core, product regulation. The Food and Drug Administration asks what a specific cellular product is, how it was processed, and what it is intended to do, and it sorts the product into a legal category that determines whether it must pass through clinical trials and premarket approval before it can be sold. The agency formalized this approach for regenerative medicine in a comprehensive policy framework announced in 2017, built on a body of regulation for human cells, tissues, and cellular and tissue-based products, abbreviated HCT/Ps.^[1]

The Mexican framework is, at its core, establishment licensing. The Ley General de Salud, México's federal health statute, requires a sanitary license for the establishments that extract, analyze, conserve, prepare, supply, bank, or transplant cells and tissues, and the health authority evaluates whether the facility has the personnel, infrastructure, equipment, and procedures the law demands.^[2] Within a licensed establishment, treatment decisions belong to licensed physicians exercising clinical judgment, as they do in most of Mexican medicine. The system asks whether the place and the people are authorized and sanitary, not whether a particular cellular product has proven efficacy for a particular disease.

Each philosophy has a coherent rationale. Product regulation treats an expanded cell preparation like a new drug because, biologically, it behaves like one: processing changes the cells, and claims about disease require evidence. Establishment licensing reflects a legal tradition in which the state credentials facilities and professionals and then leaves the practice of medicine to physicians. Neither approach was designed with the modern stem cell marketplace in mind, and both have gaps that this article will describe.

In one sentence

The United States primarily regulates the cellular product, requiring premarket proof of safety and efficacy for most stem cell therapies, while México primarily regulates the establishment, licensing the facilities and professionals that handle cells without a product-level efficacy review.

American law divides cellular products into two tiers. The lower tier, regulated under section 361 of the Public Health Service Act, covers HCT/Ps that meet strict criteria: the cells must be no more than minimally manipulated, meaning processing does not alter their relevant biological characteristics, and they must be intended for homologous use, meaning they perform the same basic function in the recipient as they did in the donor. Products that qualify do not require premarket approval; the establishment registers with the FDA and follows donor-screening and handling rules. Products that fail either criterion fall into the upper tier under section 351: they are drugs and biologics, and marketing one requires an investigational new drug application, clinical trials, and ultimately a biologics license application, the same pathway a new pharmaceutical follows.^[3]

The consequence for stem cell therapy is direct. Mesenchymal stromal cells that have been isolated and expanded in culture are more than minimally manipulated, and when they are administered for orthopedic, autoimmune, or longevity indications they are not performing the donor tissue's original basic function. Under FDA criteria, essentially every MSC therapy of the kind marketed to consumers is a section 351 drug that would require approval, and almost none have it.^[1][3]

The approved list is short but no longer empty. On December 18, 2024, the FDA approved Ryoncil (remestemcel-L), an allogeneic bone-marrow-derived MSC therapy, for steroid-refractory acute graft-versus-host disease in pediatric patients two months of age and older. It is the first and, as of this writing, the only FDA-approved MSC therapy, and its indication is narrow: a serious complication of bone-marrow transplantation, in children, after steroids have failed.^[4] No MSC product is FDA-approved for orthopedic, autoimmune, neurological, or anti-aging indications.

Enforcement is the other half of the American story, because a large domestic industry operates outside the approval pathway. The clearest documented harm came from a Florida clinic where three patients received intravitreal injections of adipose-derived cells marketed as a treatment for macular degeneration; all three suffered severe bilateral vision loss, and the case was reported in the New England Journal of Medicine in 2017.^[5] A 2016 analysis by Turner and Knoepfler had already identified at least 351 US businesses marketing unapproved stem cell interventions through 570 clinics.^[6] The FDA has pursued warning letters and court action against some of these operators; in 2019 a federal court granted a permanent injunction against the Florida company associated with the blinding cases, holding that its adipose cell product was an adulterated and misbranded drug.^[7] Enforcement, however, has not kept pace with the market, a point the next sections return to.

Mexican regulation of cells and tissues sits inside the Ley General de Salud, principally in the title governing donation, transplantation, and the disposition of human tissue. Article 315 lists the health establishments that require a sanitary license: those dedicated to the extraction, analysis, conservation, preparation, and supply of organs, tissues, and cells; those performing transplants; banks of organs, tissues, and cells; blood services; establishments handling the disposition of stem cells (células troncales); and regenerative medicine establishments. The statute directs the health authority to grant the license to establishments that have the personnel, infrastructure, equipment, instruments, and supplies the applicable provisions require.^[2] The stem cell and regenerative medicine categories are not legacy language; they were added to Article 315 by a reform published in the Diario Oficial de la Federación on April 20, 2015, which brought these activities expressly under federal sanitary licensing.^[8]

The licensing authority is COFEPRIS, the Comisión Federal para la Protección contra Riesgos Sanitarios, an arm of the federal health ministry. Its published licensing program for health-service establishments covers, among other categories, facilities performing surgical procedures and establishments operating banks of organs, tissues, and cells, including hematopoietic progenitor cells, citing Articles 198 and 315 of the statute as the legal basis.^[9] A COFEPRIS sanitary license therefore attests to specific things: that a named establishment at a named address has been authorized for defined activities involving cells and tissues, that it presented the required personnel and infrastructure, and that it operates under a responsible sanitary officer subject to inspection and sanction.

It is equally important to state what the license does not attest. COFEPRIS licensing under this framework is establishment-level authorization; it is not a premarket review of a specific cellular product's efficacy for a specific disease. Peer-reviewed analyses of the Mexican landscape make the gap explicit: a 2021 web-surveillance study of regenerative medicine clinics in the US-México border region noted that COFEPRIS regulates cell collection facilities and biobanks but that, despite proposals from the Mexican medical community dating to 2015, no specific regulatory framework for the clinical application of these therapies had been approved.^[10] Within a licensed establishment, the decision to offer a cellular protocol rests on physician discretion under general medical law, which is why the credentials and judgment of the treating physician carry more regulatory weight in México than they do in the American system.

The same study documented a verification problem that any prospective patient should understand. Of 76 Tijuana clinics identified online, 13 claimed COFEPRIS licensing on their websites, but only one matched the official government registry on both business name and address.^[10] A license that cannot be matched to the registry is, for practical purposes, a marketing claim rather than a credential, which is why verification is central to the vetting process described later in this article.

For a patient, the honest comparison runs in both directions. What FDA approval guarantees is substantial: an approved product has demonstrated safety and efficacy for its indication in controlled trials, is manufactured under enforced quality standards, and carries labeling the manufacturer is legally bound by. What the American system does not deliver is availability. One MSC product is approved, for one narrow pediatric indication.^[4] A patient seeking MSC therapy for arthritis, an autoimmune condition, or age-related decline cannot obtain an approved version of it anywhere in the United States, and the domestic market that has grown up in that vacuum is large and mostly out of compliance: by 2021, an estimated 1,480 businesses were selling unapproved stem cell interventions through 2,754 clinics, inside the country with the world's most demanding approval standard.^[11] Regulatory strictness on paper and consumer protection in practice are not the same thing.

What COFEPRIS licensing guarantees is different in kind. A genuine license means the establishment is lawful, inspected, and authorized for defined activities with cells and tissues, under a framework the federal statute has applied to stem cell and regenerative medicine establishments since 2015.^[2][8] It does not mean that any particular therapy offered inside that establishment has passed an efficacy review, because no such product-level review exists for these therapies in México.^[10] TrueCell operates under this framework, and the distinction applies to TrueCell as much as to anyone: a COFEPRIS license is not FDA approval, and treatments provided under it are properly described as not FDA-approved.

Unregulated and non-compliant actors exist in both countries. The United States has documented, litigated patient harms from unapproved products, including permanent blindness.^[5][7] México has a documented population of clinics whose licensing claims do not survive comparison with the official registry.^[10] The International Society for Stem Cell Research, whose guidelines are the field's most widely cited professional standard, cautions against the premature commercialization of unproven stem cell interventions in every jurisdiction, noting that direct-to-consumer marketing of unproven products has produced serious injuries and public confusion about which cell-based products carry real evidence.^[12] That caution does not map onto a border. It maps onto individual providers, which is why the practical question is not which country a clinic is in but whether the clinic can substantiate what it claims.

Because neither framework performs the whole job of vetting for you, the burden of evaluation falls partly on the patient in both countries. The questions below follow directly from the regulatory structure described above, and they parallel the vetting criteria in our article on stem cell safety, which covers the clinical evidence side of the same decision.

Licensure, verified rather than claimed. In México, ask for the establishment's COFEPRIS sanitary license and check that the business name and address on the license match the clinic in front of you; the Tijuana data show that a claimed license matches the registry only a fraction of the time.^[10] In the United States, ask which legal category the product occupies: a provider offering culture-expanded cells outside a registered clinical trial should be able to explain why that is lawful, and usually cannot.^[3]

Batch-level documentation. A licensed establishment still has to demonstrate what is actually in the syringe. Ask for a certificate of analysis for the specific lot you would receive, covering identity, viability, cell count, and sterility testing. How that documentation works, and what a complete certificate contains, is the subject of our cell sourcing article. A clinic in either country that cannot produce batch-level documents is asking you to take manufacturing on faith.

Physician credentials. Because Mexican law locates so much discretion with the treating physician, that physician's identity, specialty certification, and professional license are not formalities; they are the operative safeguard. Ask who evaluates you, who administers treatment, and under what specialty. The same question is worth asking in the United States, where the 2016 marketplace analysis found unapproved interventions being marketed well outside the advertising providers' specialty training.^[6]

Claims discipline. The ISSCR standard is a usable screen: providers should not represent unproven interventions as established cures, and marketing that promises results for long lists of unrelated diseases is the signature of the businesses documented in the enforcement literature.^[6][12] A trustworthy provider in either country will state which claims rest on controlled evidence, which rest on early-stage or observational data, and which are unknown. This is the standard TrueCell holds its own protocols to, and patients should hold every provider, including this one, to it.

Is stem cell therapy legal in the United States?

Some of it is. Cellular products that are minimally manipulated and used homologously may be offered without premarket approval under section 361, approved products such as Ryoncil may be prescribed within their labeled indication, and investigational therapies may be administered inside registered clinical trials.^[3][4] Most of what is actually marketed to American consumers as stem cell therapy falls into none of these categories: it is an unapproved drug under FDA criteria, and providers selling it have faced warning letters and, in documented cases, federal injunctions.^[6][7]

Is stem cell therapy legal in México?

Yes, when it is provided in an establishment holding the sanitary license that Article 315 of the Ley General de Salud requires for activities involving cells, stem cells, and regenerative medicine, by licensed physicians acting within their professional authority.^[2][9] The legality attaches to the establishment and the physician rather than to a reviewed product, and clinics operating without a verifiable license exist; published research found that most online licensing claims in Tijuana could not be matched to the official registry.^[10] Legal availability is therefore real, and so is the need to verify it.

Does a license or an approval mean a therapy works?

They mean different things, and only one of them addresses efficacy. An FDA product approval means controlled trials demonstrated safety and efficacy for a defined indication; that standard currently covers a single MSC product for one pediatric condition.^[4] A COFEPRIS establishment license means the facility is lawful and authorized for its activities; it is not evidence that any therapy offered there works.^[10] For every therapy outside the approved list, in either country, the honest description is the one the ISSCR guidelines require: an intervention whose evidence base the provider should disclose accurately, not an established cure.^[12]